Ethionamide

Indications

Ethionamide is used for: Tuberculosis

Adult Dose

Oral Tuberculosis, Active 15-20 mg/kg/day PO Initiate dose at 250 mg/day for 1-2 days; THEN increase to 250 mg twice daily for 1-2 days with gradual increases to highest tolerated dose; 750 mg/day average dose Not to exceed 1000 mg/day in 3-4 divided doses

Child Dose

Oral Tuberculosis, Active M. tuberculosis resistant to isoniazid or rifampin, or patient intolerant to drugs 10-20 mg/kg/day divided BID/TID PO OR 15 mg/kg PO qDay No more than 1000 mg/day in 3-4 divided doses

Renal Dose

Renal Impairment End-stage renal disease on hemodialysis: 250-500 mg/day CrCl <30 mL/min: 250-500 mg/day CrCl >30 mL/min: No dose adjustment necessary

Administration

Part of multi-drug regimen; not first-line treatment Take with food

Contra Indications

Hypersensitivity to ethionamide. Severe hepatic impairment.

Precautions

Patient w/ depression or other psychiatric illness, DM, porphyria, thyroid dysfunction. Hepatic or renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor serum ALT and AST at baseline and mthly; blood glucose and TSH periodically. Perform ophthalmologic exams prior to and during therapy. Evaluate CNS changes, ocular changes, and neuritis during therapy.

Pregnancy-Lactation

Pregnancy Category: C Lactation: excretion in milk unknown; use with caution

Interactions

May potentiate AR of other anti-TB drugs. Additive CNS effect w/ isoniazid and cycloserine. May cause seizures w/ cycloserine.

Adverse Effects

Side effects of Ethionamide : >10% Disorder of gastrointestinal tract (50%) Frequency Not Defined Postural hypotension Depression Dizziness Drowsiness Headache Peripheral neuropathy Psychosis Photosensitivity Rash Excessive salivation Gynecomastia Hypoglycemia Impotence Anorexia Dyspepsia Diarrhea Nausea Metallic taste Vomiting Thrombocytopenia Elevated liver transaminases Hepatitis Optic neuritis Visual changes

Mechanism of Action

Ethionamide's exact mechanism of action has not been fully elucidated, however, the drug appears to inhibit peptide synthesis. It may be bacteriostatic or bactericidal in action, depending on the concentration of drug attained at the site of infection and susceptibility of organism.